The use of VERASENSE in total knee arthroplasty results in economic benefits to the hospital or facility. Through cost savings per case of primary TKA or mitigating implant cost during revision surgery, the use of VERASENSE offers economic advantages.
of VERASENSE™ Sensor-Assisted Total Knee Arthroplasty (TKA)
COST SAVINGS PER CASE WHEN USING VERASENSE
OrthoSensor analyzed the cost-effectiveness of sensor-assisted TKA—analyzing costs and outcomes in the 90-day post-operative window—to determine if the investment in technology resulted in significant returns for providers. The primary areas in the 90-day post-operative window which VERASENSE impacts include the length of stay, physician visits, physiotherapy and manipulation under anesthesia (MUA).
Health Advances, a third party healthcare consulting firm, conducted a study involving 3 surgeon collaborators and reviewed their patient outcomes, comparing pre-VERASENSE and post-VERASENSE cases:
- Control Arm (Cases without VERASENSE technology): n=932
- Experimental Arm (Cases using VERASENSE technology): n=709
These patient outcomes were further compared with cost, outcomes and resource utilization data collected from Medicare claims, hospital records, electronic medical records (EMR), clinical, and specialty databases. The groups were controlled for age, sex, state and BMI.
The findings from this study show an average of $725 savings within the first 90 days following adoption of VERASENSE when compared to the U.S. national average.1
FACILITATING IMPLANT COST MITIGATION DURING TKA REVISION
For the “looks good, feels bad” knee, significant cost savings are possible if soft tissue imbalance – difficult to perceive and often the true problem – can be determined up front. In 58 such TKA revisions, 88% (N=36) of planned total revision cases (N=41) were changed to partial revisions through the use of VERASENSE. Theoretical implant cost savings for these cases amounted to a total of $179,640 – or $4,990 PER CASE (N=36).33